Last reviewed · How we verify
NCT04573855
TREATMENT WITH ANTI-SARS-COV-2 IMMUNOGLOBULIN IN PATIENTS WITH COVID-19
Status unknown
Phase 1, PHASE2
Last updated 5 October 2020
What this trial tests
Phase 1, PHASE2 trial testing Anti-SARS-CoV-2 immunoglobulin in Covid19 in 41 participants. Status unknown.
Timeline
1 December 2020
Primary endpoint
28 February 2021
28 February 2021
31 March 2021
Quick facts
| Lead sponsor | D'Or Institute for Research and Education |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 41 |
| Start date | 1 December 2020 |
| Primary completion | 28 February 2021 |
| Estimated completion | 31 March 2021 |
Drugs / interventions tested
- Anti-SARS-CoV-2 immunoglobulin — full drug profile →
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
D'Or Institute for Research and Education
Who can join
Adults 18 to 75, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase I/II clinical trial for safety and efficacy evaluation of treatment with anti-SARS-CoV-2 equine immunoglobulin (F(ab')2) in hospitalized patients with COVID-19 not requiring of invasive ventilation support.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Iannizzi C, Chai KL, Valk SJ, et al · · 2021 · cited 106× · PMID 34013969 · DOI 10.1002/14651858.cd013600.pub4 -
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 24× · PMID 36734509 · DOI 10.1002/14651858.cd013600.pub5 -
Polyclonal F(ab')<sub>2</sub> fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency.
Cunha LER, Stolet AA, Strauch MA, Pereira VAR, et al · · 2021 · cited 24× · PMID 34723156 · DOI 10.1016/j.isci.2021.103315 -
Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases.
Tharmalingam T, Han X, Wozniak A, Saward L. · · 2022 · cited 22× · PMID 34010089 · DOI 10.1080/21645515.2021.1886560 -
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 21× · PMID 37162745 · DOI 10.1002/14651858.cd013600.pub6 -
The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19.
Focosi D, Tuccori M, Franchini M. · · 2021 · cited 21× · PMID 33671893 · DOI 10.3390/life11020144 -
Hyperimmune immunoglobulin for people with COVID-19.
Kimber C, Valk SJ, Chai KL, Piechotta V, et al · · 2023 · cited 10× · PMID 36700518 · DOI 10.1002/14651858.cd015167.pub2 -
Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19.
Alape-Girón A, Moreira-Soto A, Arguedas M, Brenes H, et al · · 2021 · cited 9× · PMID 34552950 · DOI 10.3389/fmed.2021.743325
Verify or expand the search:
- PubMed search for NCT04573855
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other D'Or Institute for Research and Education trials
Trials by the same sponsor.
- NCT07372144 — Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment · Phase 3 · not yet recruiting
- NCT07074106 — TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC · Phase 2 · recruiting
- NCT06725537 — Comprehensive Demographics and Clinical Profile of NSCLC Patients · not yet recruiting
- NCT06002841 — Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure · Phase 1, PHASE2 · unknown
- NCT06091384 — Inspiratory Muscle Strength Training in Post-Covid Syndrome · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04573855 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by D'Or Institute for Research and Education
- Last refreshed: 5 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04573855.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing